UPDATED May 10, 2024
Companies which may present a buying opportunity after a dip in share price.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
AXSM | US$73.68 | -0.7% | -5.5% | US$3.6b | US$123.56 | PS13.9x | E65.1% | n/a | Pharmaceuticals & Biotech | ||
CAI | AU$0.13 | 4.0% | -29.7% | AU$99.0m | n/a | PB0.7x | E110.6% | n/a | Materials | ||
HHR | AU$0.007 | 0% | -76.7% | AU$19.7m | n/a | PE6.7x | E86.3% | n/a | Energy | ||
301325 | CN¥61.69 | 0.1% | -31.5% | CN¥7.4b | CN¥83.82 | PE22.3x | E24.9% | n/a | Capital Goods | ||
NEWBRY | kr3.06 | -5.3% | -44.2% | kr74.2m | kr8.00 | PS3.3x | E112.9% | n/a | Pharmaceuticals & Biotech | ||
ACI | ₹629.25 | -4.3% | 14.7% | ₹77.6b | ₹743.00 | PE19.5x | E29.0% | 0.3% | Materials | ||
301358 | CN¥39.90 | 13.9% | -6.6% | CN¥30.2b | n/a | PE20.7x | E30.3% | 1.0% | Capital Goods | ||
RCEL | US$8.26 | -5.6% | -31.8% | US$224.7m | US$25.90 | PS4.2x | E62.0% | n/a | Pharmaceuticals & Biotech | ||
AESI | US$22.72 | 3.4% | 34.6% | US$2.5b | US$26.00 | PE20.1x | E49.3% | 3.7% | Energy | ||
KCB | KSh30.05 | 1.9% | 5.4% | KSh96.6b | KSh48.65 | PB0.4x | E26.0% | 0% | Banks | ||
A101390 | ₩7,520.00 | -7.6% | -28.4% | ₩67.8b | n/a | PB3x | E100.8% | n/a | Tech | ||
300442 | CN¥28.74 | -8.5% | -5.8% | CN¥49.4b | CN¥36.36 | PE25.9x | E28.7% | 1.8% | Software | ||
DIGN | kr1.62 | 1.3% | -56.1% | kr114.2m | kr8.60 | PS1.3x | E139.0% | n/a | Healthcare | ||
CLBIO | kr10.10 | -3.3% | -43.1% | kr217.1m | kr29.00 | PS7x | E114.8% | n/a | Pharmaceuticals & Biotech | ||
FXPO | UK£0.49 | -2.8% | -53.3% | UK£287.7m | UK£1.41 | PB0.3x | E116.3% | 0% | Materials | ||
SEAPT | kr4.51 | -2.4% | -64.5% | kr1.6b | kr11.57 | PB0.9x | E54.2% | n/a | Energy | ||
ACR | AU$0.064 | -1.5% | 28.0% | AU$18.3m | n/a | PS1.6x | E115.3% | 0% | Pharmaceuticals & Biotech | ||
631 | HK$6.76 | 21.6% | -35.0% | HK$21.6b | HK$10.52 | PE10.3x | E21.2% | 2.8% | Capital Goods | ||
FLNC | US$16.73 | -20.0% | -25.6% | US$3.4b | US$29.72 | PB5.2x | E70.1% | n/a | Capital Goods | ||
XBRANE | kr0.23 | 13.6% | -99.7% | kr351.0m | n/a | PS1.5x | E93.7% | n/a | Pharmaceuticals & Biotech | ||
OX2 | kr41.84 | 5.4% | -42.9% | kr11.4b | kr70.75 | PE12.9x | E29.9% | n/a | Capital Goods | ||
CABP | UK£1.38 | -1.4% | n/a | UK£350.7m | UK£1.78 | PE15.3x | E34.6% | n/a | Diversified Financials | ||
GTI | AU$0.012 | 9.1% | -29.4% | AU$16.1m | n/a | PB2.4x | E112.4% | n/a | Software | ||
BGL | AU$1.76 | 4.5% | 35.4% | AU$2.0b | AU$2.12 | PS42.2x | E34.4% | n/a | Materials |